Announcements Trials
Browse Landscape

Phase

Phase 2 20Phase 4 4Phase NA 3Phase 3 3Phase EARLY_PHASE1 1Phase 2/3 1Phase 1/2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Metastatic Castration-Resistant Prostate Cancer (mCRPC) 1

Interventions

pembrolizumab 410Cyclophosphamide 394Carboplatin 306Gemcitabine 286Nivolumab 276Paclitaxel 274Cisplatin 252Radiotherapy 225Dexamethasone 210Bevacizumab 209fludarabine 192Docetaxel 187Rituximab 183Capecitabine 171Oxaliplatin 158Lenalidomide 157Fluorouracil 152Temozolomide 138Cytarabine 135Etoposide 128Irinotecan 124Cetuximab 123fludarabine phosphate 120Injections 118venetoclax 116Ipilimumab 115Doxorubicin 114Azacitidine 108130-nm albumin-bound paclitaxel 108Pemetrexed 107

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Metronidazole × Clear all
NCT06126731 2025-11-24

Combination Study of Antibiotics With Enzalutamide (PROMIZE)

Institute of Cancer Research, United Kingdom

Phase 1/2 Recruiting
39 enrolled
Genitourinary

Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Data powered by HemOnc (CC BY 4.0) Colophon âš¡